Aghajanian C, Blank SV, Goff BA, et al.OCEANS: A randomized double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab(Drug information on bevacizumab) in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045, 2012.
Albuquerque KV, Singla R, Potkul RK, et al: Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer. Gynecol Oncol 96:701–704, 2005.
Anderson GL, Judd HL, Kaunitz AM, et al: Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. JAMA 290:1739–1748, 2003.
Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483, 2011.
Buys SS, Partridge E, Greene MH, et al: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial. Am J Obstet Gynecol 193:1630–1639, 2005.
Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180–5186, 2007.
Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide(Drug information on cyclophosphamide) in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76–82, 2008.
Goff BA, Mandel LS, Drescher CW, et al: Development of an ovarian cancer symptom index: Possibilities for earlier detection. Cancer 109:221–227, 2007.
Gordon AN, Tonda M, Sun S, et al: Long-term survival advantage for women treated with pegylated liposomal doxorubicin(Drug information on doxorubicin) compared with topotecan(Drug information on topotecan) in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8, 2004.
Katsumata N, Yasua M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin(Drug information on carboplatin) every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331–1338, 2009.
Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331–1337, 2008.
Kauff ND, Satagopan JM, Robson ME, et al: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615, 2002.
Ledermann JA, Harter P, Gourley C, et al: Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 29(15S):abstract 5003, 2011.
Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial. J Clin Oncol 21:2460–2465, 2003.
Ozols RF, Bundy BN, Greer E, et al: Phase III trials of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 21:3194–3200, 2003.
Parmar MK, Ledermann JA, Colombo N, et al; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON 4/AGO-OVAR 2.2 trial. Lancet 361:2099–2106, 2003.
Perren TJ, Swart AM, Pfisterer J, et al; ICON7 Investigators: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496, 2011.
Pfisterer J, Plante M, Vergote I, et al: Gemcitabine(Drug information on gemcitabine)/carboplatin (GC) vs carboplatin (C) in platinum-sensitive recurrent ovarian cancer (OVCA): Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 22(14S):abstract 5005, 2004.
Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351:2489–2497, 2004.
Rustin GJ, van der Burg ME, et al: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on cnventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 27(18S):abstract 1, 2009.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236, 2011. doi:10.3322/caac.20121.
Sorbe B; Swedish-Norwegian Ovarian Cancer Study Group: Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: A randomized, controlled clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer 13:278–286, 2003.
Trimbos JB, Parmar M, Vergote I, et al; ICON and EORTC-ACTION Investigators: International Collaborative on Ovarian Neoplasm Trial 1 and Adjuvant Treatment in Ovarian Neoplasm Trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95:105–112, 2003.
Vasey PA, Jayson GC, Gordon A, et al; Scottish Gynaecological Cancer Trials Group: Phase III randomized trial of docetaxel(Drug information on docetaxel)-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian cancer. J Natl Cancer Inst 96:1682–1691, 2004.
Vergote I, Tropé CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953, 2010.
Wagner U, Marth C, Largillier R, et al: Final overall results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer 107:588–591, 2012.